Taltz, Zepbound combo yields sustained improvement at 1 year in psoriatic disease, obesity

Adults with moderate to severe psoriatic disease and overweight or obesity saw sustained or continued improvement in disease activity at 1 year with tirzepatide plus ixekizumab vs. ixekizumab monotherapy, according to a Lilly press release.One-year data from the phase 3b, randomized, double-blind, open-label TOGETHER-PsO and TOGETHER-PsA trials build on the previously reported 36-week findings